Evaluation of vaccination coverage in heart failure patients in a tertiary center.
Clinical pharmacy
Heart failure
Influenza vaccination
Pneumococcal vaccination
Vaccination coverage
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
10
02
2023
revised:
05
07
2023
accepted:
06
07
2023
medline:
31
7
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
epublish
Résumé
Despite current recommendation, vaccination coverage (VC) for patients with heart failure (HF) remains far too limited. To evaluate the VC of HF patients followed in our hospital center and investigate the barriers to vaccination and the ways to address them. This was a cross-sectional monocentric descriptive study conducted between December 2019 and January 2021 at the University Hospital of Montpellier, France. Patients with HF history hospitalized in cardiology unit (CU) and patients in a HF telemonitoring program (TP) were included. An interview was conducted by a pharmacist to find out the patient's vaccination status against influenza and pneumococcus. For non-vaccinated patients, opinion and willingness to be vaccinated were also obtained. Data from 335 patients were collected (185 in CU, 150 in TP). The mean age was 69.3 years and the proportion of males was 72%. About 65% were vaccinated against influenza in the last year (60% in CU, 72% in TP, p = 0.022) and 22% were up to date with pneumococcal vaccination (11% in CU, 35% in TP, p < 0.001). Among patients not vaccinated, 17% refused vaccination. Among unvaccinated patients who consider vaccination, 69% wanted to be vaccinated by their general practitioner (GP). The VC of HF patients remains insufficient. Patients in TP are more vaccinated than patients in CU, which could involve better management. The low rate of vaccinated patients is mainly explained by a lack of awareness. The medical team, including the clinical pharmacist by his dedicated time during medication reconciliation may play a major role in the management of hospitalized patients as well as GP's as local actors.
Sections du résumé
Background
UNASSIGNED
Despite current recommendation, vaccination coverage (VC) for patients with heart failure (HF) remains far too limited.
Aims
UNASSIGNED
To evaluate the VC of HF patients followed in our hospital center and investigate the barriers to vaccination and the ways to address them.
Methods
UNASSIGNED
This was a cross-sectional monocentric descriptive study conducted between December 2019 and January 2021 at the University Hospital of Montpellier, France. Patients with HF history hospitalized in cardiology unit (CU) and patients in a HF telemonitoring program (TP) were included. An interview was conducted by a pharmacist to find out the patient's vaccination status against influenza and pneumococcus. For non-vaccinated patients, opinion and willingness to be vaccinated were also obtained.
Results
UNASSIGNED
Data from 335 patients were collected (185 in CU, 150 in TP). The mean age was 69.3 years and the proportion of males was 72%. About 65% were vaccinated against influenza in the last year (60% in CU, 72% in TP, p = 0.022) and 22% were up to date with pneumococcal vaccination (11% in CU, 35% in TP, p < 0.001). Among patients not vaccinated, 17% refused vaccination. Among unvaccinated patients who consider vaccination, 69% wanted to be vaccinated by their general practitioner (GP).
Conclusions
UNASSIGNED
The VC of HF patients remains insufficient. Patients in TP are more vaccinated than patients in CU, which could involve better management. The low rate of vaccinated patients is mainly explained by a lack of awareness. The medical team, including the clinical pharmacist by his dedicated time during medication reconciliation may play a major role in the management of hospitalized patients as well as GP's as local actors.
Identifiants
pubmed: 37519644
doi: 10.1016/j.heliyon.2023.e18080
pii: S2405-8440(23)05288-X
pmc: PMC10372228
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e18080Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Roubille Francois reports a relationship with Pfizer Inc that includes: consulting or advisory. CHAPET Nicolas reports a relationship with Pfizer Inc that includes: consulting or advisory.
Références
Am J Kidney Dis. 2012 Dec;60(6):959-65
pubmed: 22694948
J Clin Med. 2021 Sep 22;10(19):
pubmed: 34640328
CMAJ. 2016 Oct 4;188(14):E342-E351
pubmed: 27455981
Hum Vaccin Immunother. 2021 Jan 2;17(1):162-169
pubmed: 32429734
Ann Pharm Fr. 2021 Jan;79(1):77-85
pubmed: 33049251
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
PLoS One. 2013 Aug 23;8(8):e72476
pubmed: 24009684
Health Serv Res. 2010 Oct;45(5 Pt 1):1287-309
pubmed: 20579128
JACC Heart Fail. 2017 Mar;5(3):194-203
pubmed: 28161238
Eur J Heart Fail. 2020 Jun;22(6):985-994
pubmed: 32438483
JACC Heart Fail. 2016 Feb;4(2):152-158
pubmed: 26746371
Arch Intern Med. 1986 Nov;146(11):2179-85
pubmed: 3778047
Eur J Heart Fail. 2013 Jul;15(7):808-17
pubmed: 23537547
Vaccine. 2011 Oct 19;29(45):8073-6
pubmed: 21864625
Thorax. 2009 Jul;64(7):567-72
pubmed: 19321465
Eur Heart J. 2022 Feb 10;43(6):440-441
pubmed: 34922348
Clin Rheumatol. 2021 Feb;40(2):575-579
pubmed: 33030631
Arch Intern Med. 2008 Apr 28;168(8):847-54
pubmed: 18443260
Heart. 2007 Sep;93(9):1137-46
pubmed: 17699180
Presse Med. 2001 Jun 16-23;30(21):1044-8
pubmed: 11471275
Hum Vaccin Immunother. 2020 Sep 1;16(9):2136-2143
pubmed: 32614656
J Med Internet Res. 2015 Mar 12;17(3):e63
pubmed: 25768664
Thorax. 2013 Jul;68(7):658-63
pubmed: 23535212
J Prev Med Public Health. 2019 Sep;52(5):323-332
pubmed: 31588702